Petition Dismissed - Rule 46.

Joint stipulation for dismissal of the petition for a writ of certiorari pursuant to Rule 46 filed.

Brief of Federal Respondents in opposition filed.

Motion to extend the time to file a response is granted and the time for Catalyst Pharmaceuticals, Inc. to file a response is further extended to and including July 25, 2022.

Motion of Catalyst Pharmaceuticals, Inc. to extend the time to file a response from June 24, 2022 to July 25, 2022, submitted to The Clerk.

Motion to extend the time to file a response is granted and the time is further extended to and including July 11, 2022, for all respondents.

Motion of the Solicitor General to extend the time to file a response from June 10, 2022 to July 11, 2022, submitted to The Clerk.

Motion to extend the time to file a response is granted and the time for Catalyst Pharmaceuticals, Inc. to file a response is extended to and including June 24, 2022.

Motion of Catalyst Pharmaceuticals, Inc. to extend the time to file a response from June 10, 2022 to June 24, 2022, submitted to The Clerk.

Motion to extend the time to file a response is granted and the time is extended to and including June 10, 2022, for all respondents.

Motion to extend the time to file a response from May 11, 2022 to June 10, 2022, submitted to The Clerk.

Petition for a writ of certiorari filed. (Response due May 11, 2022)

Jacobus Pharmaceutical Company, Inc., Petitioner, represented by Marisa Christina Maleck

Catalyst Pharmaceuticals, Inc., Respondent, represented by Philip J. Perry

Xavier Becerra, Secretary of Health and Human Services, et al., Respondent, represented by Elizabeth B. Prelogar